Vertex kept at market perform by JMP

JMP Securities analyst Adam Cutler maintained Vertex Pharmaceuticals, Inc. at market perform following the company's commercialization deal with Johnson & Johnson for VX-950 for hepatitis C virus. Vertex will get $165 million upfront and $380 million in milestones. Shares of the Cambridge, Mass.-based pharmaceutical company were up $4.68, or 14.61%, at $36.71 on volume of 15,111,702 shares versus the three-month running average of 1,682,130 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.